A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Adults (Phase I) and to Healthy Adolescents and Adults (Phase II)
Latest Information Update: 24 May 2024
At a glance
- Drugs GSK 4023393A (Primary) ; DTaP vaccine; Meningococcal vaccine group B OMV Novartis; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications Meningococcal infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 24 May 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 21 Mar 2024 This trial has been completed in Sweden according to European Clinical Trials Database record
- 08 Mar 2024 Planned End Date changed from 19 Jan 2024 to 30 Sep 2024.